Studies related to Bone Mineral Density and Vitamin D

Risedronate And Ergocalciferol Prevent Hip Fracture In Elderly Men With Parkinson Disease

Effect None
Trial Design Double blind
Trial Length 6+ Months
Number of Subjects 121
Sex Both Genders
Age Range 65+
Body Types Overweight, Average
Notes for this study:
Two years supplementation of 1,000 IU of vitamin D2 was unable to prevent hip fractures and preserve bone mineral density in persons with Parkinson's disease, while the active group of Risedronate plus vitamin D2 was effective.